"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...

The company ended 2024 with $862m in cash, which it says will fund operations through the first half of 2027, including its three ongoing Phase III clinical trials. Intellia is prioritising NTLA-2002, ...

PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...